Drugs / MK-8266
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01263314 | Nov 2010 → Feb 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1 | NCT01244035 | Aug → Dec 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01096160 | Mar → Nov 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1 | NCT01025791 | Nov 2009 → May 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK8266 | “MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.” NCT01244035 ↗4“A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)” NCT01096160 ↗ |
| Route | Oral | “Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form.” NCT01025791 ↗ |